Member Info for crumbs

I noticed in BioNtechs pre IPO matterial... 2019 is the only year that Lilly who have a deal with them to come up with a clinical TCR product have not paid anything to BioNtech.... got to hurt BioNtech that... as looks like nothing is coming from that 2015 initiated deal.... yet is it possible Lindy will have within 6 months a clinically viable TCR product for BioNtech to take forwards? .... would BioNtech offer it up to Lilly so as to get more deal funds? what would Lilly think if scancell can do the job lol... hmm who knows lol but I guess it is a watch this space and an exciting arm to scancells multiple potentials

As with so much here we can only hope........ certainly seems a better chance now of getting something from pharma than a few years back.... I never discount that RNS arriving that both values and validates scancells approach

I meant is 'now' a commercial niche product... not sure if Amgen has made back all they have invested in it though.. but possibly

I thought p values were what is most important.... being able to get enough data to confidently know what results would be in a bigger cohort or in other words to know how effective a treatment will be out in the real world and so how commercially viable it is... The first SCIB1 trial gave quite a lot of such data... we know it is best as an Adjuvant treatment post resection we also know there is no point in running it in mono in late-stage non resected as the benefit will not be better than current CI's .... though it probably would be almost as good..... which when you look at values currently attached to CI's is quite something... If you got big money behind you you can do stuff... look at T Vec a product that is surely of lesser value than SCIB1 yet Amgen have managed to get it approved and it is not a commercial niche product... the clout of having funds that!

Retweet:
The next opportunity to improve #immunotherapy will come include appropriately primed T-cells. #Vaccine #ESMO19
https://twitter.com/gulleyj1/status/1177867273677295616

It's one those subscription-only articles but guess from the title we get the gist.... and keeps RG earning his keep lol...
Think boom appertained scancell are not attending this particular ESMO

Yes, it is great news when treatments prove effective but it is not as though that is it melanoma is now cured ...next!... no not at all

I think you will find that treatment will have to involve the immune system in some way.. unless you are talking about replacing bodies with machines or something :)

Boom
https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/paris-lap-poster.pdf

notice... modi3

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/paris-lap-poster.pdf

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/paris-2019-peptide-selection-final.pdf

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/paris-2019-hcit-final.pdf

I would think so but only after their presentation so this evening (UK time)) .... something of interest in all these papers... how much donated human blood are scancell getting through!!! :) ...

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/2811-cicon19-paris-jc.pdf

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/bip-cicon19-paris-final.pdf

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/modi1-cicon19-paris-final.pdf

Worth a look... wonder who there was taking an interest too....onwards to tomorrows

Associated with scancell - Yamamoto Fumiichiro

http://www.carrerasresearch.org/Yamamoto_Fumiichiro

An interesting little flurry that

Probably a case of the timing of scancell needing her coincided with the turmoil at Immunocre over its future .... but she is certainly a great asset for scancell ....

Interesting read about our Oxford neighbours the much-vaunted UK biotech unicorn.... Sam Paston may have made a shrewd move..

'That Immunocore is trying to raise money should not shock anyone familiar with the past two years’ goings on at this private UK biotech. The bigger surprise is how the group has managed to last this long without going back to investors.

Immunocore famously burned through most of a record $320m series A raise with little to show for it beyond an interesting scientific idea and the defenestration of its chief and several other key executives. There will no doubt be disappointment that its reported £100m ($124m) raise is not a flotation, and that it is a major down round, but in reality the writing had been on the wall for some time.

In May one of Immunocore’s key backers, the beleaguered UK financier Neil Woodford’s Woodford Patient Capital Trust (WPCT), was forced by financial regulators to cut the carrying value of one of its unquoted holdings. That holding was widely assumed to have been Immunocore.'
https://www.evaluate.com/vantage/articles/news/corporate-strategy/new-reality-immunocore

Yes possibly an RNS tomorrow... I'm surprised RG responded on twitter he rarely answers questions on it... He could indeed do a #cicon19 tweet ... why they have not so far I do not know but hopefully the posters will be on the website by next week for our perusal

Yes, Paul Rennert is there...

Hw would be better named McMoodyBlue :)

Scancells presentations are tomorrow and Friday... if you go on #cicon19 on Twitter you will see it is a well-attended event... even our old mouse gate buddy Rennert is there :)

A185 is interesting as is about the adjuvant of ISA's, Melief also in attendance at CICON19
' Linking the TLR2 agonists to the peptides allowed the vaccine dose to
be reduced 10-100 fold without loss of anti-tumor activity. These
studies suggest that low dose of citrullinated peptides linked to
TLR2 ligand should be rapidly translated to the clinic for the treatment of cancer. Furthermore, ovarian cancer patients show a CD4
proliferative response to one or more of the citrullinated peptides
which is similar to that in healthy donors. These results suggest
that Modi-1 could be an effective vaccine for ovarian cancer patients.'

promising for the upcoming trial